Pelthos Therapeutics Business Summary

Pelthos Therapeutics Inc. (PTHS) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of innovative topical treatments for cutaneous infectious diseases. The company generates revenue primarily through product sales, anchored by its flagship asset ZELSUVMI (berdazimer) topical gel, 10.3%, which is the first and only FDA-approved at-home prescription treatment for molluscum contagiosum. Pelthos operates within the pediatric and dermatologic infectious disease segments, recently expanding its portfolio through the strategic acquisition of XEPI (ozenoxacin) for impetigo and XEGLYZE (abametapir) for head lice. Its business model leverages the proprietary NITRICIL™ nitric oxide-based technology platform to address high unmet needs in the dermatology market. Direct competitors include Verrica Pharmaceuticals (YCANTH), Biofrontera Inc., and manufacturers of generic topical antibiotics like mupirocin; Pelthos distinguishes itself as a market leader by offering non-invasive, patient-administered alternatives to traditional in-office procedures and older-generation topical therapies. The company’s leadership is led by CEO Scott M. Plesha, who brings over 30 years of pharmaceutical experience, including a successful tenure as President and CCO of BioDelivery Sciences (BDSI) and a senior leadership role at Salix Pharmaceuticals. The executive team was significantly bolstered following the July 2025 merger with Channel Therapeutics, which brought in Frank Knuettel II as Chief Financial Officer, a veteran executive with extensive experience in life sciences M&A and public company management. Other key leaders include Chief Commercial Officer Sai Rangarao and Melvin Whitehead, who oversees manufacturing and supply chain operations. The company is backed by notable institutional investors including Murchinson Ltd., which led a $50.1 million private placement, and Ikarian Capital. The Board of Directors features prominent industry figures such as Independent Chairman Peter Greenleaf (CEO of Aurinia Pharmaceuticals) and Todd Davis (CEO of Ligand Pharmaceuticals), reflecting a strong pedigree of commercial and strategic expertise.